Mario Gaio

department of experimental medicine

H指数:9

被引数:255

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database

报告涉及利拉鲁肽、司美格鲁肽和替尔泊肽的自杀与自伤相关事件模式：欧洲药物警戒数据库的数据

Frontiers in Pharmacology

IF4.8

2026-08-280

Semaglutide Exposure During Pregnancy: Results from the FAERS Database

妊娠期间司美格鲁肽暴露：FAERS数据库的结果

Pharmaceuticals

IF4.8

2026-08-140

Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance

揭露假冒司美格鲁肽：基于EudraVigilance的真实世界安全性数据分析

Frontiers in Pharmacology

IF4.8

2026-04-290

OAAI

Safety profile of FLT3 inhibitors in acute myeloid leukemia: a systematic review and meta-analysis of adverse events

FLT3抑制剂在急性髓系白血病中的安全性概况：不良事件的系统评价与荟萃分析

Clinical and Experimental Medicine

IF3.5

2026-02-230

OAAI

Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination

COVID-19疫苗接种后欧洲自身免疫和风湿病安全报告的不成比例性分析

SCIENTIFIC REPORTS

IF3.9

2025-04-270

Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database

PHARMACOLOGICAL REPORTS

IF3.8

2024-10-230

PRE

Pregnancy Recommendations Solely Based on Preclinical Evidence Should Be Integrated with Real-World Evidence: A Disproportionality Analysis of Certolizumab and Other TNF-Alpha Inhibitors Used in Pregnant Patients with Psoriasis

PHARMACEUTICALS

IF4.8

2024-07-071

OAAI

The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database

BIOMEDICINES

IF3.9

2023-09-154

OAAI

Multisystem Inflammatory Syndrome in Children Following COVID-19 Vaccination: A Sex-Stratified Analysis of the VAERS Database Using Brighton Collaboration Criteria

PHARMACEUTICALS

IF4.8

2023-08-301

OAAI

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database

BIOMEDICINES

IF3.9

2023-08-012

OAAI

COVID-19 Vaccines and Atrial Fibrillation: Analysis of the Post-Marketing Pharmacovigilance European Database

新型冠状病毒肺炎疫苗与心房颤动: 上市后欧洲药物警戒数据库分析

BIOMEDICINES

IF3.9

2023-05-301

OAAI

Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data

成人恶性血液病患者car-t细胞治疗后的晚期复发: 来自个体数据的系统评价和荟萃分析的明确证据

PHARMACOLOGICAL RESEARCH

IF10.5

2023-04-016

OAAI

Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study

使用EudraVigilance药物警戒数据库监测5至11岁儿童的mRNA新型冠状病毒肺炎疫苗的安全性: CoVaxChild研究

VACCINES

IF3.4

2023-02-096

OAAI

Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-10-0314

OAAI

Did the COVID-19 Pandemic Affect Contrast Media-Induced Adverse Drug Reaction's Reporting? A Pharmacovigilance Study in Southern Italy

JOURNAL OF CLINICAL MEDICINE

IF2.9

2022-08-306

OAAI

Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines

解开棘手的问题: 新型冠状病毒肺炎后和mRNA新型冠状病毒肺炎疫苗后的心肌炎和心包炎

PHARMACEUTICALS

IF4.8

2022-04-258

OAAI

The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study

PHARMACEUTICALS

IF4.8

2022-02-2511

OAAI

Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System

PHARMACEUTICALS

IF4.8

2021-06-2531

OAAI

PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database

DRUG SAFETY

IF3.8

2020-12-2231

OAAI

Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data

PHARMACEUTICALS

IF4.8

2020-09-218

OAAI

Mario Gaio

个人简介

教育背景

工作经历

荣誉奖项

研究方向